Theravance Biopharma Inc. (NASDAQ:TBPH) rose 3% during trading on Friday . The company traded as high as $22.96 and last traded at $22.92, with a volume of 236,799 shares traded. The stock had previously closed at $22.26.

Several research analysts have issued reports on the company. Zacks Investment Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 19th. Bank of America Corp. downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Thursday, May 5th. Leerink Swann assumed coverage on Theravance Biopharma in a research note on Thursday, May 12th. They issued an “outperform” rating and a $26.00 price target on the stock. Finally, Guggenheim assumed coverage on Theravance Biopharma in a research note on Monday, June 20th. They issued a “buy” rating and a $30.00 price target on the stock. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $24.75.

The company’s market cap is $1.09 billion. The firm’s 50-day moving average price is $22.94 and its 200-day moving average price is $19.50.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.14. The firm had revenue of $18.40 million for the quarter, compared to the consensus estimate of $18.69 million. On average, analysts forecast that Theravance Biopharma Inc. will post ($4.24) earnings per share for the current year.

A hedge fund recently raised its stake in Theravance Biopharma stock. OppenheimerFunds Inc. boosted its position in shares of Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned 2.92% of Theravance Biopharma worth $18,086,000 as of its most recent SEC filing.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.